Reboxetine addition in patients with mirtazapine-resistant depression: A case series

Clinical Neuropharmacology

Volumn 29, Issue 4, 2006, Pages 192-196

  López Muñoz, Francisco ^a   Rubio, Gabriel ^b   Alamo, Cecilio ^a   García García, Pilar ^a   Pardo, Antonio ^c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Combination treatment; Major depressive disorder; Mirtazapine; Reboxetine; Resistant depression

Indexed keywords

MIRTAZAPINE; REBOXETINE; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; MIANSERIN; MORPHOLINE DERIVATIVE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG RESISTANCE; EVALUATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; NERVOUSNESS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; STOMACH DISCOMFORT; TREATMENT FAILURE; XEROSTOMIA; DRUG COMBINATION; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; MORPHOLINES;

EID: 33748751900     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000228211.19818.14     Document Type: Article

References (27)

1. Versiani M, Moreno R, Ramakers-van Moorsel C, et al. Comparative efficacy antidepressants study group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005;19:137-146.
2. Nierenberg AA, Amsterdam JD. Resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51:S39-S47.
3. Nemeroff CB. Augmentation strategies in patients with refractory depression. Depression 1997;4:169-181.
4. Rojo JE, Ros S, Agüera L, et al. Combined antidepressant: clinical experience. Acta Psychiatr Scand 2005;112:25-31.
5. Devarajan S, Dursun SM. Citalopram plus reboxetine in treatment-resistant depression. Can J Psychiatr 2000;45:489-490.
6. Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SRRI resistant patients. Hum Psychopharmacol Clin Exp 2000;15:143-145.
7. Lam RW, Wan DDC, Cohen NL, et al. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry 2002;63:685-693.
8. Rubio G, San L, López-Muñoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J Affect Disord 2004;81:67-72.
9. Dodd S, Horgan D, Malhi GS, et al. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 2005;89:1-11.
10. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60:45-49.
11. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-188.
12. DeBoer TH, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988;27:399-408.
13. Rubio G, San L, López-Muñoz F, et al. Tratamiento de combinación con reboxetina en pacientes con depresión mayor no respondedores o con respuesta parcial a inhibidores selectivos de la recaptación de serotonina. Actas Esp Psiquiatr 2003;31:315-324.
14. Tanum L. Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand 2000;101(suppl 402):37-40.
15. Ratner S, Laor N, Brosntein Y, et al. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005;44:428-433.
16. Gallassi R, Di Sarro E, Morreale A, et al. Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord 2006;91:243-250.
17. Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002;63:826-837.
18. Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry 2000;61:403-408.
19. De la Gándara J, Ágüera L, Ros S, et al. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand 2005;112:32-35.
20. Ros S, Agüera L, De la Gándara J, et al. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand 2005;112:14-24.
21. Hawley, CJ, Sivakumaran, T, Ochocki, M, et al. Coadministration therapy with reboxetine and serotonin specific reuptake inhibitors in twenty-four patients with major depression. 13th Congress of European College of Neuropsychopharmacology. Munich, Germany, September 9-13, 2000.
22. Serreti A, Lucca A, Cusin C, et al. Associazione di reboxetine nella depressione resistente a SSRI effect of reboxetine augmentation in SSRI resistant patients. Giorn Ital Psicopatol 2001;7:9-14.
23. De la Gándara J, Rojo JE, Ros S, et al. Neuropharmacological basis of combining antidepressant. Acta Psychiatr Scand 2005;112:11-13.
24. Joffe RT. Substitution Therapy in patients with major depression. CNS Drugs 1999;11:175-180.
25. Schule C, Bahai T, Laakmann G. Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Neuroendocrinology 2004;79:54-62.
26. Cuenca E, Alamo C, López-Muñoz F, et al. Perfil farmacodinámico y farmacocinético de un nuevo antidepresivo: reboxetina. Psiquiatr Biol 1999;6:86-90.
27. De la Gándara J, Agüera L, Ferre F, et al. Eficacia y seguridad de la asociación de antidepresivos. Actas Esp Psiquiatr 2002;30:75-84.